| . | Overall . | Non-recurrence . | Recurrence . | P value . |
|---|---|---|---|---|
| . | (n= 213) . | (n= 139) . | (n= 74) . | . |
| Clinical characteristics | ||||
| Age (years) | 55 ± 11 | 55 ± 9 | 55 ± 15 | 0.99 |
| Male gender, n (%) | 165 (77) | 108 (78) | 57 (77) | 0.91 |
| Body surface area (m2) | 2.1 ± 0.2 | 2.1 ± 0.2 | 2.1 ± 0.2 | 0.18 |
| Body mass index (kg/m2) | 26.5 ± 3.6 | 26.4 ± 3.4 | 26.8 ± 3.8 | 0.41 |
| CHADS2 score ≥2, n (%) | 15 (7) | 13 (9) | 2 (3) | 0.07 |
| Duration of atrial fibrillation (months) | 67 ± 60 | 68 ± 56 | 65 ± 66 | 0.75 |
| History of cardioversion, n (%) | 114 (54) | 68 (49) | 46 (62) | 0.07 |
| History of persistent atrial fibrillation, n (%) | 46 (22) | 19 (14) | 27 (36) | <0.001 |
| Failed anti-arrhythmic drugs (n) | 3.2 ± 1.3 | 3.2 ± 1.4 | 3.2 ± 1.2 | 0.92 |
| Hypertension, n (%) | 88 (41) | 53 (38) | 35 (47) | 0.20 |
| Diabetes, n (%) | 9(4) | 8 (6) | 1 (1) | 0.13 |
| Medication | ||||
| ACE-inhibitor, n (%) | 48 (23) | 32 (23) | 16 (22) | 0.82 |
| Angiotensin-II receptor blocker, n (%) | 58 (27) | 34 (24) | 24 (32) | 0.21 |
| Class IC anti-arrhythmic drug, n (%) | 75 (35) | 54 (39) | 21 (28) | 0.13 |
| Class III anti-arrhythmic drug, n (%) | 121 (57) | 77 (55) | 44 (59) | 0.57 |
| . | Overall . | Non-recurrence . | Recurrence . | P value . |
|---|---|---|---|---|
| . | (n= 213) . | (n= 139) . | (n= 74) . | . |
| Clinical characteristics | ||||
| Age (years) | 55 ± 11 | 55 ± 9 | 55 ± 15 | 0.99 |
| Male gender, n (%) | 165 (77) | 108 (78) | 57 (77) | 0.91 |
| Body surface area (m2) | 2.1 ± 0.2 | 2.1 ± 0.2 | 2.1 ± 0.2 | 0.18 |
| Body mass index (kg/m2) | 26.5 ± 3.6 | 26.4 ± 3.4 | 26.8 ± 3.8 | 0.41 |
| CHADS2 score ≥2, n (%) | 15 (7) | 13 (9) | 2 (3) | 0.07 |
| Duration of atrial fibrillation (months) | 67 ± 60 | 68 ± 56 | 65 ± 66 | 0.75 |
| History of cardioversion, n (%) | 114 (54) | 68 (49) | 46 (62) | 0.07 |
| History of persistent atrial fibrillation, n (%) | 46 (22) | 19 (14) | 27 (36) | <0.001 |
| Failed anti-arrhythmic drugs (n) | 3.2 ± 1.3 | 3.2 ± 1.4 | 3.2 ± 1.2 | 0.92 |
| Hypertension, n (%) | 88 (41) | 53 (38) | 35 (47) | 0.20 |
| Diabetes, n (%) | 9(4) | 8 (6) | 1 (1) | 0.13 |
| Medication | ||||
| ACE-inhibitor, n (%) | 48 (23) | 32 (23) | 16 (22) | 0.82 |
| Angiotensin-II receptor blocker, n (%) | 58 (27) | 34 (24) | 24 (32) | 0.21 |
| Class IC anti-arrhythmic drug, n (%) | 75 (35) | 54 (39) | 21 (28) | 0.13 |
| Class III anti-arrhythmic drug, n (%) | 121 (57) | 77 (55) | 44 (59) | 0.57 |
ACE-inhibitor, angiotensin-converting enzyme inhibitor.
| . | Overall . | Non-recurrence . | Recurrence . | P value . |
|---|---|---|---|---|
| . | (n= 213) . | (n= 139) . | (n= 74) . | . |
| Clinical characteristics | ||||
| Age (years) | 55 ± 11 | 55 ± 9 | 55 ± 15 | 0.99 |
| Male gender, n (%) | 165 (77) | 108 (78) | 57 (77) | 0.91 |
| Body surface area (m2) | 2.1 ± 0.2 | 2.1 ± 0.2 | 2.1 ± 0.2 | 0.18 |
| Body mass index (kg/m2) | 26.5 ± 3.6 | 26.4 ± 3.4 | 26.8 ± 3.8 | 0.41 |
| CHADS2 score ≥2, n (%) | 15 (7) | 13 (9) | 2 (3) | 0.07 |
| Duration of atrial fibrillation (months) | 67 ± 60 | 68 ± 56 | 65 ± 66 | 0.75 |
| History of cardioversion, n (%) | 114 (54) | 68 (49) | 46 (62) | 0.07 |
| History of persistent atrial fibrillation, n (%) | 46 (22) | 19 (14) | 27 (36) | <0.001 |
| Failed anti-arrhythmic drugs (n) | 3.2 ± 1.3 | 3.2 ± 1.4 | 3.2 ± 1.2 | 0.92 |
| Hypertension, n (%) | 88 (41) | 53 (38) | 35 (47) | 0.20 |
| Diabetes, n (%) | 9(4) | 8 (6) | 1 (1) | 0.13 |
| Medication | ||||
| ACE-inhibitor, n (%) | 48 (23) | 32 (23) | 16 (22) | 0.82 |
| Angiotensin-II receptor blocker, n (%) | 58 (27) | 34 (24) | 24 (32) | 0.21 |
| Class IC anti-arrhythmic drug, n (%) | 75 (35) | 54 (39) | 21 (28) | 0.13 |
| Class III anti-arrhythmic drug, n (%) | 121 (57) | 77 (55) | 44 (59) | 0.57 |
| . | Overall . | Non-recurrence . | Recurrence . | P value . |
|---|---|---|---|---|
| . | (n= 213) . | (n= 139) . | (n= 74) . | . |
| Clinical characteristics | ||||
| Age (years) | 55 ± 11 | 55 ± 9 | 55 ± 15 | 0.99 |
| Male gender, n (%) | 165 (77) | 108 (78) | 57 (77) | 0.91 |
| Body surface area (m2) | 2.1 ± 0.2 | 2.1 ± 0.2 | 2.1 ± 0.2 | 0.18 |
| Body mass index (kg/m2) | 26.5 ± 3.6 | 26.4 ± 3.4 | 26.8 ± 3.8 | 0.41 |
| CHADS2 score ≥2, n (%) | 15 (7) | 13 (9) | 2 (3) | 0.07 |
| Duration of atrial fibrillation (months) | 67 ± 60 | 68 ± 56 | 65 ± 66 | 0.75 |
| History of cardioversion, n (%) | 114 (54) | 68 (49) | 46 (62) | 0.07 |
| History of persistent atrial fibrillation, n (%) | 46 (22) | 19 (14) | 27 (36) | <0.001 |
| Failed anti-arrhythmic drugs (n) | 3.2 ± 1.3 | 3.2 ± 1.4 | 3.2 ± 1.2 | 0.92 |
| Hypertension, n (%) | 88 (41) | 53 (38) | 35 (47) | 0.20 |
| Diabetes, n (%) | 9(4) | 8 (6) | 1 (1) | 0.13 |
| Medication | ||||
| ACE-inhibitor, n (%) | 48 (23) | 32 (23) | 16 (22) | 0.82 |
| Angiotensin-II receptor blocker, n (%) | 58 (27) | 34 (24) | 24 (32) | 0.21 |
| Class IC anti-arrhythmic drug, n (%) | 75 (35) | 54 (39) | 21 (28) | 0.13 |
| Class III anti-arrhythmic drug, n (%) | 121 (57) | 77 (55) | 44 (59) | 0.57 |
ACE-inhibitor, angiotensin-converting enzyme inhibitor.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
